Who Owns McKesson Medical-Surgical?

• Parent Company: McKesson Corporation
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NYSE: MCK

• Founded: 1987
• Founders: McKesson Corporation (internal development)

• Founded: 1833
• Headquarters: Irving, Texas, USA
• Company Type: Publicly Traded
• Stock: NYSE: MCK
• Revenue: approximately $354 billion (FY2025, year ended March 2025)
• Employees: Approximately 51,000

Visit McKesson Corporation website

• Headquarters: Richmond, Virginia, USA
• Manufacturing / Operations: United States, Canada

McKesson Medical-Surgical operates under McKesson Corporation's comprehensive environmental sustainability framework, which includes ambitious climate action initiatives and green building standards. As part of McKesson's commitment to creating solutions for a healthier environment, the division implements sustainable practices across its distribution and supply chain operations.

McKesson has introduced Green Building Standards (GBS), a customized framework that delivers measurable environmental benefits across the company's global portfolio. In fiscal year 2025, nine McKesson facilities achieved GBS certification, with ongoing assessments to ensure facilities meet rigorous environmental standards that combine energy efficiency, flexibility, and occupant wellness.

The company has made significant progress in reducing greenhouse gas emissions across its value chain, achieving the goal of having 70% of suppliers by spending set SBTi-approved GHG reduction targets. These climate targets align with limiting global warming to 1.5°C, positioning McKesson among more than 10,000 companies worldwide committed to reducing GHG emissions.

McKesson Medical-Surgical benefits from the company's investments in renewable energy through Virtual Power Purchase Agreements (VPPAs). In fiscal 2025, McKesson invested in a new VPPA with Recurrent Energy's 100-MWac/134-MWdc Liberty Solar plant in Liberty County, Texas, which generates enough electricity to power approximately 15,000 homes annually and reduces carbon emissions by 182,000 metric tons.

For cold chain product transportation, McKesson has implemented a reusable system that reduces waste while maintaining product quality and safety. This system includes reusable outer shells, inner linings, and phase change materials designed to maintain 2-8 degrees Celsius for 24 hours. The company has also piloted electric vehicles and implemented advanced routing software to enhance fuel efficiency and decrease carbon emissions across its transportation fleet.

McKesson Corporation has received multiple awards and recognitions for its business performance and corporate responsibility initiatives. In fiscal 2024, McKesson reported strong financial results with consolidated revenues of $309.0 billion, demonstrating the company's position as a leader in healthcare distribution and services.

While specific awards for McKesson Medical-Surgical division are not publicly disclosed, the parent company has been recognized for its sustainability achievements, including its SBTi-approved climate targets and green building initiatives. McKesson's environmental programs have been acknowledged for their innovation in healthcare supply chain sustainability.

The company's leadership in healthcare distribution has been recognized through various industry acknowledgments, particularly for its role in advancing health equity and supporting healthcare access in underserved communities. McKesson launched pilot initiatives aimed at advancing health equity, with Avondale, Ohio selected as the first activation site to support access to essential pharmacy services.

McKesson's financial performance and operational excellence have positioned the company as one of the largest healthcare distributors globally, with recognition for its ability to deliver meaningful outcomes for customers, partners, patients, and communities.

McKesson Corporation, the parent company of McKesson Medical-Surgical, has faced several legal challenges and controversies in recent years, primarily related to opioid distribution and pricing practices.

In August 2024, McKesson along with Cencora Inc. and Cardinal Health Inc. agreed to a $300 million class action settlement resolving allegations from health insurers and benefit plans regarding the distributors' role in the opioid epidemic. The settlement, disclosed in federal court in Cleveland, Ohio, covered third-party payers like union funds that paid for overprescribed opioids and subsequent addiction treatment. The distributors did not admit wrongdoing as part of the settlement.

Earlier, McKesson agreed to pay a record $150 million settlement to resolve allegations of failing to report suspicious orders of controlled substances. The U.S. Attorney's Office for the District of New Jersey announced the settlement, emphasizing that pharmaceutical companies serve as the first line of defense in prescription opioid abuse prevention.

In March 2024, a federal appeals court revived a whistleblower lawsuit accusing McKesson of providing drug pricing tools to doctors for free to induce them to purchase drugs from the company. The 3-0 decision by the 2nd U.S. Circuit Court of Appeals allowed the kickback lawsuit to proceed, raising questions about the company's marketing and sales practices.

Additionally, McKesson reached a $141 million settlement resolving allegations it misled investors about profits from a price-fixing conspiracy among generic drug manufacturers. The settlement, to be paid by the company's insurers, was disclosed in an SEC filing and addressed investor concerns about the company's involvement in generic drug pricing controversies.